Background-After myocardial ischemia, extracellular matrix (ECM) deposition occurs at the site of the focal injury and at the border region. Methods and Results-We have applied a novel proteomic method for the analysis of ECM in cardiovascular tissues to a porcine model of ischemia/reperfusion injury. ECM proteins were sequentially extracted and identified by liquid chromatography tandem mass spectrometry. For the first time, ECM proteins such as cartilage intermediate layer protein 1, matrilin-4, extracellular adipocyte enhancer binding protein 1, collagen ␣-1(XIV), and several members of the small leucine-rich proteoglycan family, including asporin and prolargin, were shown to contribute to cardiac remodeling. A comparison in 2 distinct cardiac regions (the focal injury in the left ventricle and the border region close to the occluded coronary artery) revealed a discordant regulation of protein and mRNA levels; although gene expression for selected ECM proteins was similar in both regions, the corresponding protein levels were much higher in the focal lesion. Further analysis based on Ͼ100 ECM proteins delineated a signature of earlyand late-stage cardiac remodeling with transforming growth factor-␤1 signaling at the center of the interaction network. Finally, novel cardiac ECM proteins identified by proteomics were validated in human left ventricular tissue acquired from ischemic cardiomyopathy patients at cardiac transplantation. Conclusion-Our findings reveal a biosignature of early-and late-stage ECM remodeling after myocardial ischemia/reperfusion injury, which may have clinical utility as a prognostic marker and modifiable target for drug discovery. (Circulation. 2012;125:789-802.)
L eft ventricular (LV) remodeling after myocardial infarction is an important predictor of progression to heart failure and an early marker of increased morbidity and mortality. 1 Initiated by the loss of cardiomyocytes and cardiac function, the remodeling process is characterized by differentiation of cardiac fibroblasts into myofibroblasts, exhibiting secretory, proliferative, and contractile functions in the postinjury state. Myofibroblasts contribute to the compensatory tissue replacement and interstitial fibrosis by effectively regulating the extracellular matrix (ECM) turnover, 2 primarily in the area of the focal injury but also in the border region. 3, 4 Once initiated, the remodeling process is continu-ous, even after the initial injury has abated, leading to systolic and diastolic impairment. Accumulation of collagen disrupts electric coupling with increased arrhythmic susceptibility. Perivascular fibrosis impairs oxygen diffusion and exacerbates ongoing tissue ischemia and fibrosis. 5 Current antiremodeling strategies targeting the renin-angiotensin-aldosterone system delay or prevent the development of heart failure largely by reducing the extent of interstitial collagen deposition. 6 Because fibrosis is probably reversible before the maladaptive changes of the collagen network and development of a mature scar, 7, 8 it is pertinent to characterize the different stages of ECM remodeling.
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Thus far, proteomics studies have been performed on whole-heart tissue 9, 10 or on subcellular fractions, 11 including myofilaments, 12 mitochondria, 13 and cytosolic 14 and nuclear 15 extracts, but an in-depth analysis of the cardiac ECM has not been reported to date. The aim of the present study is to characterize ECM remodeling after myocardial infarction by applying a recently developed proteomics method 16 to a porcine model of ischemia/reperfusion (I/R) injury. The human-like physiology and anatomy of pigs facilitate comparisons of different cardiac regions to establish an accurate temporal and spatial pattern of the ECM remodeling process.
Methods
An expanded Methods section is available in the online-only Data Supplement at http://circ.ahajournals.org.
Porcine Model of I/R injury
Nineteen 3-month-old pigs were randomly assigned into the I/R group (nϭ13) or the control group (Ctrl; nϭ6). Ischemia was induced by inserting an inflatable catheter and occluding the left anterior descending coronary artery for 120 minutes (see Movie I in the online-only Data Supplement). All procedures followed the European Agreement of Vertebrate Animal Protection for Experimental Use (86/609).
Proteomic Analysis
ECM proteins were extracted with an adaptation of a recently published method 16 and analyzed by liquid chromatography tandem mass spectrometry as detailed in the online-only Data Supplement.
Human Cardiac Tissue
Cardiac tissue samples were obtained from patients undergoing cardiac transplantation at the A Coruña Hospital under approval from the Galician Ethics Committee for Research. Control tissues were obtained from unused donor hearts from the A Coruña Hospital following guidelines of Spanish Royal Decrees 2070/1999 and 1301/2006, which regulate the obtainment of human tissues for clinical and research purposes. Written informed consent was obtained from all patients.
Statistical Analysis
Student t tests were used to compare protein expression between early and late fibrosis and control samples in the focal lesion and the border zone close to the coronary artery. False discovery rates were calculated with the R package QVALUE with standard settings. 17 Protein spectral counts were log transformed and z transformed in an attempt to create data with normal distributions and to increase the signal of low-abundance proteins. Z score transformation of spectral counts was performed as follows: The expression measurement for each protein was adjusted to have a mean of 0 and an SD of 1 across all conditions. Biological interpretation was based on relevant scientific literature. 18 Principal component analysis was performed with Matlab version 2009a (The Mathworks Ltd). The 20 most significantly expressed proteins across all groups were identified on the basis of 1-way ANOVA. The effects of treatment (transforming growth factor-␤ [TGF␤, hypoxia, TGF␤ plus hypoxia) and time (24 and 48 hours) on ECM protein expression in cardiac fibroblasts were assessed by 2-way ANOVAs followed by Bonferroni post tests. A value of PϽ0.05 was considered significant.
Results

Porcine Model of I/R Injury
Pigs were subjected to I/R injury and euthanized either 15 days (I/R15; nϭ9) or 60 days (I/R60; nϭ4) later. Six animals served as Ctrl ( Table I in the online-only Data  Supplement) . Infarct development and location were confirmed by ECG ( Figure I in the online-only Data Supplement). LV function and size were assessed by echocardiography ( Figure 1A and Movie I in the online-only Data Supplement). The LV ejection fraction was 60.9Ϯ10.0% in Ctrl compared with 34.3Ϯ10.3% in pigs at day 15 (meanϮSD; Pϭ0.01) and 30.0Ϯ5.1% at day 60 (Pϭ0.001) after injury. LV wall thickness was reduced from 11.4Ϯ1.8 mm in controls to 6.6Ϯ2.5 mm in the I/R15 group (meanϮSD; PϽ0.001) and to 5.6Ϯ2.1 mm in the I/R60 group (PϽ0.001). A representative macroscopic image is shown in Figure 1B . Fifteen days after I/R injury, cardiac tissue was sampled from 2 different regions: the border zone close to the coronary artery (I/R15 COR) and the focal lesion of the LV (I/R15 LV) where the ischemic injury is most pronounced. Equivalent regions were sampled in Ctrls (COR Ctrl and LV Ctrl). Four pigs were kept for 60 days after the operation to provide reference samples for late fibrosis (I/R60 LV). To visualize the extent of fibrosis, tissue sections were stained with Masson trichrome stain. Counterstaining was performed with hematoxylin and eosin ( Figure 1C ).
Identification of Extracellular Proteins
Four animals per group (Ctrl, I/R15, and I/R60) were used for proteomics. Heart samples were consecutively incubated with 0.5 mol/L sodium chloride (NaCl), 0.1% SDS, and 4 mol/L guanidine hydrochloride (guanidine-HCl) to decellularize and sequentially extract extracellular-space proteins. 16 The effectiveness of the decellularization procedure (SDS) was confirmed by electron microscopy (Figure 2A ). The NaCl and guanidine-HCl extracts were separated by SDS -PAGE ( Figure II in the online-only Data Supplement); the entire lane was divided into a series of gel bands; and proteomic analysis was performed on each of them with a high-mass-accuracy tandem mass spectrometer (LTQ Orbitrap XL, ThermoFisher Scientific). In total, 139 extracellular-space proteins (the Table) were identified with a minimum of 2 high-confidence peptides (Tables II and III in the online-only Data Supplement for NaCl and guanidine-HCl extracts, respectively). Among the identified proteins were 17 proteoglycans, 25 collagen subunits, and 84 glycoproteins; the remaining 13 were proteins known to be associated with ECM (apolipoproteins, proteases, etc). As expected, NaCl extracts were enriched with proteins of the extracellular space and newly synthesized ECM proteins, which are not heavily crosslinked on the interstitial matrix. Guanidine-HCl extracts instead contained predominantly proteoglycans, glycoproteins, and collagens ( Figure 2B ). Importantly, several proteins were identified for the first time in the cardiac ECM (see the footnote in the Table) . Representative COR indicates border region close to the occluded coronary artery; I/R15, ischemia/reperfusion with euthanasia at 15 days; Ctrl, control; LV, focal injury in the left ventricle; I/R60, ischemia/reperfusion with euthanasia at 60 days; NA, not applicable; EGF, epidermal growth factor; and SPARC, secreted protein acidic and rich in cysteine. P values were derived from unpaired Student t tests with unequal variance (Note that every time protein expression in the majority of samples from 1 of the 2 groups compared was undetectable, the t test was not performed). False discovery rates were calculated with the R-package QVALUE. *FDRϽ5%.
†Proteins that returned 0 hits in a PubMed query of title/abstracts combined with any of the following terms: "myocardial infarction," "cardiac remodeling," or "ischemic remodeling." tandem mass spectrometry spectra of these proteins are provided in Figure III in the online-only Data Supplement. Protein ambiguity was resolved with the Scaffold software, and peptides assigned to Ͼ1 protein are highlighted in Table IV in 
Differential Expression Analysis
A comparison of protein changes during cardiac ECM remodeling was performed with label-free quantification as previously described 12 (the Table) . Classic remodeling markers such as collagen type I and III were increased in both extracts, indicating active ECM remodeling with continuous synthesis of ECM proteins (NaCl) and subse-quent incorporation to the interstitial matrix (guanidine-HCl). At 15 days, few ECM proteins changed in the border zone significantly (I/R15 COR; Figure 3A ), but pronounced changes were observed in the focal lesion (I/R15 LV; Figure 3B ), ie, for cartilage intermediate layer protein 1 (CILP-1), asporin, adipocyte enhancer binding protein 1 (AEBP-1), and TGF␤-induced protein ig-h3 (BGH3). Cartilage and bone-related proteins such as aggrecan (PGCA) and chondroadherin (CHAD) were found only at day 60 ( Figure 3C) . Notably, several of these proteins are downstream targets of TGF␤-1, a major profibrotic factor (Figure 4 ). However, interactions for CILP-1, asporin, or aggrecan had to be inferred from experiments on other tissues, ie, cartilage, because these proteins are currently not in public cardiac matrix interaction databases. 
Bioinformatic Analysis
Principal component analyses were used for visual display of regional and temporal differences in the ECM after I/R injury ( Figure 5A and 5B for NaCl and guanidine-HCl extracts, respectively). The matrix profile of the border zone (I/R15 COR), focal lesion (I/R15 LV), and late fibrosis (I/R60 LV) was clearly distinct from the respective controls (COR Ctrl and LV Ctrl), suggesting a high reproducibility of our proteomic technique. Expression patterns of the top 20 most differentially expressed proteins across all samples (identified by 1-way ANOVA) are shown in Figure 5C and 5D (NaCl and guanidine-HCl extracts, respectively). Expression changes covering different groups of ECM proteins were selected for further validation and are highlighted in Figure 5 .
Validation
Using real-time polymerase chain reaction, we detected an induction of CILP1, asporin, aortic carboxipeptidase (ACLP; the extracellular isoform of AEBP-1), BGH3, and collagen XIV and XVIII ( Figure 6A ) in the same tissue specimen used for proteomic analysis (Figure 6B and 6C) .
Although the mRNA levels of these ECM components were highly correlated in the focal (I/R15 LV) and border (I/R15 COR) regions ( Figure 6D ), the spectral counts for the corresponding proteins were markedly higher in the focal lesion ( Figure 6E ). We confirmed the upregulation of asporin, dermatopontin, ACLP/AEBP-1, biglycan, and periostin in the infarcted LV by immunoblotting ( Figure  7A) . In contrast, the inactive latency-associated peptide-TGF␤-1 complex was reduced ( Figure 7A and 7B) , suggesting that most of the TGF␤-1 present within cardiac tissue is bioactive after I/R injury, which is consistent with the upregulation of thrombospondin 1 (the Table) , the most potent activator of TGF␤-1 signaling. 19 Indeed, TGF␤-1 but not hypoxia induced the expression of BGH3 and dermatopontin in isolated pig cardiac fibroblasts ( Figure  7C ). Induction of asporin was observed after a combined stimulation by hypoxia and TGF␤-1. Expression levels for ACLP/AEBP-1 remained similar to those of controls. In agreement with this finding, positive staining for ACLP/ AEBP-1 in LV tissue was found to be predominantly intracellular in cardiomyocytes rather than cardiac fibroblasts. In contrast, periostin, which is expressed within cardiac fibroblasts in response to exogenous TGF␤-1 but not in cardiomyocytes, 20 revealed a distinct extracellular distribution pattern ( Figure 7D ). Weaker extracellular and pericellular immunostaining was apparent for dermatopon- tin and BGH3. Finally, the presence of novel cardiac ECM proteins was validated in patients undergoing cardiac transplantation surgery for ischemic heart failure. Clinical characteristics are provided in Table VII in the online-only Data Supplement. For each patient, representative tissue sections are shown in Figure IV in the online-only Data Supplement. Immunofluorescence staining for CILP, asporin, and dermatopontin was seen in ischemic porcine (I/R15 LV; Figure 8A ) and human ( Figure 8B ) LV tissue.
Discussion
This study has several important aspects. First, by diverging from the traditional focus on intracellular proteins, we used a sequential extraction procedure in combination with state-of-the-art proteomics. Using this conceptually novel approach, we reveal previously unknown cardiac ECM components and provide important insights into ECM remodeling by region and stage of fibrosis. The extensive proteomic comparison allowed for the first time a coexpression analysis of ECM proteins during early and late stages of cardiac remodeling.
A Proteomics Approach for ECM
Thus far, proteomics studies investigating cardiac diseases have been focused on intracellular proteins, with little emphasis on ECM and proteins in the extracellular space.
To overcome the bias toward the cellular proteome and the failure to detect cardiac ECM proteins in proteomics analysis, we have applied a novel method optimized for the analysis of cardiac ECM. 16 This method is based on decellularization and a sequential extraction procedure to enrich for ECM components. It provides a simplified subproteome abundant in matrix proteins that can be interrogated by label-free quantification. This is important because no proteomic technology can currently resolve the entire complexity of the mammalian proteome, and there is a tradeoff between sensitivity and quantitative accuracy. Previous quantitative comparisons applying shotgun proteomics to cardiac tissue had to exclude fractions containing myofilament proteins to alleviate the severe dynamic range limitations stemming from highly abundant contractile components. 14 Similarly, in our method, the decellularization step is essential to improve sensitivity and quantitative accuracy in the ECM subproteome. 16 Unlike any other cardiac proteomics study published to date, in this study, newly synthesized matrix proteins or loosely bound factors in the extracellular space were extracted before the tissues were decellularized. 21 Then, integral ECM components such as proteoglycans, glycoproteins, or cross-linked collagens, which are not dissolved in conventional extraction buffers, were solubilized under harsh conditions.
Advantages of Proteomics
The primary ECM deposited after myocardial infarction is composed of fibrin and plasma-derived fibronectin, which serve as the initial scaffold for the migration and expansion of fibroblasts and the infiltration of inflammatory cells before a more definitive ECM is synthesized with newly formed matrix components. 22, 23 Transcriptomics provides valuable insights into the expression and regulation of ECM proteins at the mRNA level. Some ECM-associated proteins, however, which are not expressed by cardiac cells but are plasma derived, remain undetected. Moreover, microarrays provide only a snapshot of mRNA expression at a particular time point. In contrast, proteomics measures the actual ECM that has accumulated over time as the net effect of protein synthesis and protein degradation. Compared with conventional antibody-based techniques, a proteomics screening method is better suited to capture the complex interactions during ECM remodeling, but it cannot reveal the spatial localization of these ECM proteins within the cardiac tissue. In our study, the ischemic injury and the subsequent fibrosis were less pronounced in the border region compared with the focal lesion. At the time of harvest, however, gene expression of selected ECM proteins was similar in the 2 regions, suggesting that a profibrotic program had been initiated in both areas. Gene transcripts have a much shorter half-life than proteins, and a stable protein is not necessarily encoded by a stable mRNA. Moreover, ECM remodeling is subject to an intricate network of control, including microRNAs for translational repression. The lack of correlation between protein and mRNA levels demonstrates the complementary nature of transcriptomics and proteomics in the study of cardiac ECM remodeling.
The Importance of ECM in Cardiac Remodeling
Myocardial fibrosis is a hallmark of cardiac remodeling in response to ischemia and is closely linked to arrhythmogenicity and impairment of both systolic and diastolic function. Although cardiomyocytes constitute 70% of the cardiac tissue mass, they represent only about one third of the cells. The other predominant cell type within the heart is the fibroblast. 5 Fibroblasts actively synthesize and secrete ECM and contribute to the propagation of the electric signals that orchestrate cardiac contraction. 24 In disease, the transition of fibroblasts to myofibroblasts, regulated in part by TGF␤-1, induces a profibrotic state that contributes to cardiac dysfunction with consequent impairment of contractile properties and relaxation along with rhythm disturbance by affecting electric signal propagation and arrhythmogenicity. 25 The cardiac ECM not only provides structural support but also retains soluble growth factors and regulates their distribution. 26 For example, fibroblast growth factor and vascular endothelial growth factor bind avidly to the heparan sulfate component of many ECM proteoglycans. Growth factors also bind to ECM proteins themselves, without the involvement of glycosaminoglycans; ie, vascular endothelial growth factor binds to specific fibronectin type III domains present in both fibronectin and tenascin-C, supporting the notion that the presentation of growth factor signals by ECM proteins is an important part of ECM function. 26 Thus, a comprehensive description of the ECM is essential to decipher the complex, multivalent signals that are presented to cells during cardiac remodeling. ). Note that mRNA expression was highly correlated but protein levels were markedly different in the 2 regions. I/R15 indicates ischemia/reperfusion with euthanasia after 15 days.
Novel Downstream Targets of TGF␤-1
TGF␤ is a critical profibrotic molecule in the heart, 23 but some of its downstream targets identified in this study either have not been reported in cardiac tissue thus far or have not been studied in the context of cardiac remodeling. For example, CILP1 was described as a cartilage protein. 27 It contains thrombospondin type I repeats that potentially modulate its anchoring ability to other ECM components, including glycosaminoglycans and, interestingly, TGF␤-1. 28, 29 In our proteomics analysis, the highest levels of CILP1 were observed in the focal lesion 15 days after I/R injury, when CILP1 may act by antagonizing TGF␤-1, as reported by studies in other tissues. 30 Similarly, asporin is a critical regulator of TGF␤-1 in articular cartilage. It blocks the interaction of TGF␤-1 with the TGF␤ type II receptor 31,32 on the cell surface and inhibits the canonical TGF␤-1/Smad signaling pathway. Yet, the presence of CILP1 or asporin has not been demonstrated in cardiac tissue at the protein level. Other modulators of TGF␤-1 signaling have not been studied in the context of cardiac remodeling. Dermatopontin enhances TGF␤-1 activity, accelerates collagen fibril formation, and stabilizes collagens. 33 BGH3 is an extracellular reporter of TGF␤-1 activity. 34 It serves as a communication link between fibroblasts and its ECM environment by mediating adhesion via integrin binding and inhibits cell proliferation. 35 In addition, the presence of the cartilage protein aggrecan has been reported only in hearts of developing chicken embryos 36 ; further studies in adult cardiac tissue have not yet been performed. Thus, our study will serve as an important reference for future investigations exploring the function of these novel proteins and developing transgenic animal models to study their contribution to the cardiac remodeling process.
Conclusions
Using a porcine model of I/R injury and state-of-the-art mass spectrometry, we provide the first proteomic characterization of cardiac ECM remodeling. This innovative strategy allowed novel insights that may be useful for the early detection of adverse remodeling events and the prediction of the likelihood of the occurrence of heart failure. For example, characteristic changes for early and late fibrosis could be monitored by molecular imaging techniques over the course of disease or in response to therapy to personalize its delivery. Figure 7 . Role of transforming growth factor-␤1 (TGF␤-1). A, Immunoblots confirming higher levels of asporin, aortic carboxipeptidase-like protein (ACLP/ AEBP1), dermatopontin (DERM), biglycan (PGS1), and periostin (POSTN). Their upregulation coincided with a loss of the latency-associated peptide-transforming growth factor-␤1 (TGF␤-1) complex, which migrates at its characteristic molecular weight of Ϸ40 kDa. Silverstained images demonstrating equal loading are provided in Figure II in the onlineonly Data Supplement. B, Quantification for latency-associated peptide-TGF␤-1 complex by densitometry. ***PϽ0.001. C, Effects of TGF␤-1 and hypoxia on the expression of TGF␤-induced protein ig-h3 (BGH3), DERM, asporin, and ACLP/ AEBP-1 in cardiac fibroblasts (nϭ9, means and 95% confidence intervals). Two-way ANOVA was used to test for differences across treatment groups (control [Ctrl], TGF␤-1, hypoxia, and TGF␤-1 and hypoxia) and time points of measurement (24 and 48 hours). Bonferroni posttests for multiple comparisons with controls are shown. ***PϽ0.001. D, Staining for POSTN, BGH3, DERM, and ACLP/ AEBP-1. Left, Negative controls (staining with secondary antibodies only). Note the extracellular distribution of POSTN but the intracellular localization of AEBP-1. 
